Asston Pharmaceuticals Limited (BSE: 544445) is a Navi Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹164 Cr, it ranks #2,755 by market cap among the 6,197 Indian listed companies on FinBizNet, and #38 of 63 in Pharmaceuticals. At ₹152.00 (as of 10 Nov 2026), the share price is 0.9% below its 52-week high of ₹153.40 and 144.3% above its 52-week low of ₹62.21. The share price is up 82.9% over one year and up 90.0% over three months.
| Current Price | ₹152.00 |
|---|---|
| Market Cap | ₹164 Cr |
| BSE Code | 544445 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 30.6 |
| Return on Assets | -1.32% |
| 52-Week Range | ₹62.21 – ₹153.40 |
| 1-Year Price Change | +82.9% |
| 3-Month Price Change | +90.0% |
| Beta (1Y) | 0.02 |
| Headquarters | Navi Mumbai, Maharashtra |
| Website | www.asstonpharmaceuticals.com |
Delivery averaged 100.0% of traded volume across 15 BSE sessions (15 Oct 2026 – 6 Nov 2026).
Asston Pharmaceuticals Limited manufactures pharmaceutical products in India, West Africa, South Africa, and Asian countries. The company provides tablets, such as aceclofenac, albendazole, aminophylline, artemether and lumefantrine, ascorbic acid chewable, azithromycin, b-complex, calcium, cholecalciferol with folic acid, cefixime, cetirizine, ciprofloxacin, co-trimoxazole, cyproheptadine, dexamethasone, diclofenac, ferrous sulphate, folic acid, glucose, griseofulvin, levofloxacin, loperamide HCL, losartan potassium, mebendazole, metformin hydrochloride sustained release, metformin hydrochloride, metronidazole, multivitamin, nitrofurantoin, ofloxacin and ornidazole, pantoprazole, paracetamol, paracetamol, phenylephrine HCL, chlorpheniramine maleate and caffeine, prednisolone, pregabalin SR and methylcobalamin, pyridoxine HCL, rifampicin and isoniazid, rifampicin, isoniazid, pyrazinamide and ethambutol HCL, sildenafil, tadalafil, telmisartan, and zinc sulphate. It also offers capsules,
1. Pharmaceuticals-This segment engages in the manufacturing and selling of pharmaceutical formulations and nutraceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹54,788 Cr | 35.3 | 34.46% | ₹1,814 Cr | -8.2% |
| Ajanta Pharma Limited | ₹42,432 Cr | 40.2 | 25.39% | ₹1,794 Cr | +35.7% |
| Emcure Pharmaceuticals Ltd | ₹35,726 Cr | 38.6 | 19.57% | ₹2,820 Cr | +67.0% |
| Piramal Pharma Ltd | ₹31,892 Cr | n/m | -4.00% | ₹2,617 Cr | +21.7% |
| RUBICON RESEARCH LIMITED | ₹27,601 Cr | 108.9 | 19.14% | ₹576 Cr | +186.9% |
| Caplin Point Laboratories Ltdte | ₹17,770 Cr | 27.8 | 19.94% | ₹610 Cr | +25.0% |
| Pfizer Ltd. | ₹16,646 Cr | 23 | 17.16% | ₹727 Cr | -24.3% |
| Eris Lifesciences Ltd | ₹16,096 Cr | 25.6 | 18.07% | ₹892 Cr | -21.1% |
| Asston Pharmaceuticals Limited | ₹164 Cr | 30.6 | — | — | +82.9% |
Listed by market capitalisation. Ratios are shown for context only.
Asston Pharmaceuticals Limited is trading at ₹152.00, with a market capitalisation of ₹164 Cr.
Asston Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Asston Pharmaceuticals Limited has a P/E of 30.6.
Asston Pharmaceuticals Limited is listed on the BSE under the scrip code 544445.
Asston Pharmaceuticals Limited's share price is up 82.9% over one year and up 90.0% over three months. Its 52-week range is ₹62.21 to ₹153.40.
Data as of 10 Nov 2026. Descriptive market data only — not investment advice.